AR099148A1 - HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1) - Google Patents
HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1)Info
- Publication number
- AR099148A1 AR099148A1 ARP150100162A ARP150100162A AR099148A1 AR 099148 A1 AR099148 A1 AR 099148A1 AR P150100162 A ARP150100162 A AR P150100162A AR P150100162 A ARP150100162 A AR P150100162A AR 099148 A1 AR099148 A1 AR 099148A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- programmed death
- human antibodies
- immunomodulator
- receiver
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente proporciona anticuerpos que se unen a la proteína muerte programada-1 (PD-1) co-inhibidor de células T, y métodos de uso. En diversas formas de realización de la presente, los anticuerpos son anticuerpos completamente humanos que se unen a PD-1. En ciertas formas de realización, se proporcionan moléculas de unión a antígeno multi-específicas que comprenden una primera especificidad de unión que se une a PD-1 y una segunda especificidad de unión que se une a un antígeno de tejido autoinmune, otro co-inhibidor de células T, un receptor de Fc o un receptor de células T. En algunas formas de realización, los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad de PD-1, proporcionando así un medio para el tratamiento de una enfermedad o trastorno tal como cáncer o una infección viral crónica. En otras formas de realización, los anticuerpos son útiles para mejorar o estimular la actividad de PD-1, proporcionando así un medio para el tratamiento de, por ejemplo, un trastorno o enfermedad autoinmune.This provides antibodies that bind to the programmed death protein-1 (PD-1) co-inhibitor of T cells, and methods of use. In various embodiments of the present, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, multi-specific antigen binding molecules are provided that comprise a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another co-inhibitor of T cells, an Fc receptor or a T cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing the activity of PD-1, thereby providing a means for the treatment of a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for improving or stimulating the activity of PD-1, thus providing a means for the treatment of, for example, an autoimmune disorder or disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461930576P | 2014-01-23 | 2014-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099148A1 true AR099148A1 (en) | 2016-07-06 |
Family
ID=58698425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100162A AR099148A1 (en) | 2014-01-23 | 2015-01-21 | HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1) |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR099148A1 (en) |
MA (1) | MA49604B1 (en) |
-
2015
- 2015-01-21 AR ARP150100162A patent/AR099148A1/en unknown
- 2015-01-23 MA MA49604A patent/MA49604B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA49604A1 (en) | 2022-02-28 |
MA49604B1 (en) | 2022-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124747T1 (en) | HUMAN ANTIBODIES TO PD-1 | |
CL2018000908A1 (en) | Anti-lag3 antibodies and their use to treat cancer or viral infection. | |
CY1124437T1 (en) | HUMAN ANTIBODIES AGAINST PD-L1 | |
CL2017000310A1 (en) | Anti tigit antibodies | |
NI201800027A (en) | ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGENS BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES OF THEM. | |
CO2017007619A2 (en) | Human antibodies against Ebola virus glycoprotein | |
CY1121542T1 (en) | ANTIBODY MOLECULES TO PD-1 AND THEIR USE | |
CO2019000968A2 (en) | Zika anti-virus antibodies and methods of use | |
CO2018001485A2 (en) | Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3 | |
UY36757A (en) | MONOCLONAL ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY | |
CO2018000809A2 (en) | Antibodies for cd40 | |
PE20180484A1 (en) | T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES | |
BR112017013385A2 (en) | antibodies to tigit | |
UY36458A (en) | HUMAN ANTIBODIES FOR INFLUENZA HEMAGLUTININE. | |
ECSP15025845A (en) | ANTI-CEACAM5 ANTIBODIES AND USES OF THEM | |
CO2020001981A2 (en) | Proteins that bind to nkg2d, cd16, and flt3 | |
UY37630A (en) | PHARMACEUTICAL COMBINATION, KIT, GUEST CELL THAT PRODUCES IT AND ITS USE IN METHODS FOR CANCER TREATMENT | |
AR099148A1 (en) | HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1) | |
BR112016030291A2 (en) | combination therapy | |
AR099147A1 (en) | HUMAN ANTIBODIES AGAINST PD-L1 | |
AR120118A2 (en) | ANTI-TIGIT ANTIBODIES | |
AR105171A1 (en) | ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY | |
AR105714A1 (en) | MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN B7-H3 AND CD3, AND USES OF THE SAME | |
AR099798A1 (en) | METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT | |
AR104480A1 (en) | HUMAN ANTIBODIES AGAINST THE GLICOPROTEIN OF THE ÉBOLA VIRUS |